KA/EN
Register
Medicines reference
Search
Search
Active substance

Cyclopentolate

Favourites

Anticholinergic mydriatic, cycloplegic. Registered in Georgia: 1 human medicine. Forms: eye drops.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Cyclopentolate
Dose Species Indication Route Frequency Source
1 drops Dog, Cat Maintenance Into the eye 1–2 doses in the first 24 hours, then every other day
DGAV SPC 2020
Official product label (SPC), DGAV, Portugal
Approved by Portugal's Directorate-General for Food and Veterinary Medicine (DGAV) as part of the product's authorisation. It applies to that product as authorised there.
Midriacil 10 mg/ml colírio, solução para cães, gatos e equinos - Resumo das Características do Medicamento Veterinário
Direção-Geral de Alimentação e Veterinária (Portugal), 2020
Before use

Safety information

Known Contraindications

  • Critical
    Do not use cyclopentolate in cats with increased intraocular pressure or in patients with angle-closure glaucoma.
  • Warning (Cat)
    Cyclopentolate can increase intraocular pressure in cats and is systemically absorbed. Monitor intraocular pressure. Salivation is reported in cats; vomiting, tremor, and confusion occur rarely.
Latin name
Cyclopentolate
Georgian name
ციკლოპენტოლატი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 1 forms
Products
Cicloplegicedol
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Cicloplegicedol 10 mg/ml (1%), Eye drops

eye drops, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive cycloplegia/mydriasis for ocular pain and pupillary spasm associated with corneal ulcer and/or anterior uveitis
7.3/10
Good
vetman assessment

Cicloplegicedol

10 mg/ml (1%), eye drops, human medicine
Assessed clinical scopeDog · Adjunctive cycloplegia/mydriasis for ocular pain and pupillary spasm associated with corneal ulcer and/or anterior uveitis · Into the eye
Care settingVeterinary ophthalmic treatment after examination, with reassessment and IOP/tear monitoring where indicated.
vetman score 7.3/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-046398 · Verified on 15 Oct 2026 Off-label use

A credible off-label transfer from a composition-matched authorised veterinary comparator for ocular pain and pupillary spasm, supported by canine pharmacodynamics; useful with ophthalmic diagnosis, monitoring and minimum necessary duration.

Regulatory and scientific credibility7.5/10

The exact human product is currently authorised in Georgia and Portugal with a transparent composition/leaflet; a current Portuguese veterinary comparator matches strength and preservative, but Cicloplegicedol itself has no veterinary authorisation and clinical transfer is not product equivalence.

Clinical efficacy7.5/10

The authorised matching-strength veterinary comparator supports relief of ciliary spasm/ocular pain and prevention of posterior synechiae in corneal ulcer and/or anterior uveitis, with species pharmacodynamics; controlled diseased-eye outcome trials for the exact human product were not located.

Safety and tolerability7.0/10

A small healthy-Beagle study found no significant IOP or tear-production change after one drop, but diseased eyes and repeated exposure remain less certain; ocular irritation, hypersensitivity, benzalkonium exposure and systemic antimuscarinic effects still require selection and monitoring.

Clinical practicality7.0/10

A calibrated dropper and once/twice-first-day then alternate-day comparator regimen are workable in ophthalmic care, but restraint, aseptic technique, ocular re-examination and spacing other drops remain necessary.

Full-course cost-effectiveness-

A current Georgian exact-pack price and role-specific full-course/procedure cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Human medicine. All canine/feline use of this exact Cicloplegicedol presentation is off-label; the authorised Portuguese veterinary comparator supports transfer but does not make the exact product veterinary-authorised.
  • Healthy-Beagle one-drop data did not show a significant IOP/tear change, but diseased eyes and repeated exposure were not established; monitor patients with abnormal IOP or tear production.
  • Systemic absorption remains possible despite topical use. Use the minimum justified number of drops and monitor for salivation, vomiting, tremor, weakness, confusion or unusual behaviour.
  • Stop and reassess persistent/new ocular irritation, pain, chemosis, marked photophobia, keratitis or hypersensitivity. The exact product contains benzalkonium chloride 0.1 mg/ml, which may irritate the ocular surface.
  • Other antimuscarinic medicines may potentiate systemic effects. Cyclopentolate may antagonise cholinergic miotics/antiglaucoma medicines such as pilocarpine or carbachol; review the complete medication plan.
  • Separate other ophthalmic medicines by at least 5–10 minutes. Do not mix products in one preparation unless compatibility is established.
  • Avoid dropper-tip contact with the eye, lids or any surface; do not share one bottle between animals. Inspect solution clarity and bottle integrity before use.
  • Discard 28 days after first opening. Store at no more than 25°C, tightly closed in the original outer pack, protected from light and humidity.
  • Avoid during pregnancy unless the veterinarian concludes that expected benefit outweighs risk; use during lactation only after an individual benefit-risk assessment.
  • Overdose or ingestion can cause anticholinergic toxicity, including hypotension and respiratory/CNS depression. Treat as urgent exposure and contact veterinary toxicology/emergency care.
Assessment sources
  1. Cicloplegicedol exact leaflet2022
  2. Midria current register2026
  3. Midria current SPC2025
  4. Healthy Beagle cyclopentolate2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Dog Diagnostic mydriasis and cycloplegia for fundus examination or refractive assessment
7.4/10
Good
vetman assessment

Cicloplegicedol

10 mg/ml (1%), eye drops, human medicine
Assessed clinical scopeDog · Diagnostic mydriasis and cycloplegia for fundus examination or refractive assessment · Into the eye
Care settingClinic-administered ophthalmic diagnostic use with planned timing, ocular examination and species-specific post-dose observation.
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-046398 · Verified on 15 Oct 2026 Off-label use

A useful intermediate-duration diagnostic cycloplegic/mydriatic with direct canine pharmacodynamic data and a transparent exact product; plan timing and do not mistake prolonged dilation for proof of refractive accuracy in every patient.

Regulatory and scientific credibility7.5/10

The exact human product is currently authorised in Georgia and Portugal with a transparent composition/leaflet; a current Portuguese veterinary comparator matches strength and preservative, but Cicloplegicedol itself has no veterinary authorisation and clinical transfer is not product equivalence.

Clinical efficacy7.0/10

A direct 15-Beagle study confirms one-drop mydriasis beginning at 30 minutes and lasting up to 72 hours, while the exact human leaflet supports cycloplegic refraction; refractive-accuracy and diseased-eye data for this exact product remain limited.

Safety and tolerability7.5/10

A small healthy-Beagle study found no significant IOP or tear-production change after one drop, but diseased eyes and repeated exposure remain less certain; ocular irritation, hypersensitivity, benzalkonium exposure and systemic antimuscarinic effects still require selection and monitoring.

Clinical practicality8.0/10

One-drop administration and predictable onset are practical for clinic diagnostics, although prolonged dilation and the absence of one validated universal veterinary refraction protocol require planned timing and counselling.

Full-course cost-effectiveness-

A current Georgian exact-pack price and role-specific full-course/procedure cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Human medicine. All canine/feline use of this exact Cicloplegicedol presentation is off-label; the authorised Portuguese veterinary comparator supports transfer but does not make the exact product veterinary-authorised.
  • Healthy-Beagle one-drop data did not show a significant IOP/tear change, but diseased eyes and repeated exposure were not established; monitor patients with abnormal IOP or tear production.
  • Systemic absorption remains possible despite topical use. Use the minimum justified number of drops and monitor for salivation, vomiting, tremor, weakness, confusion or unusual behaviour.
  • Stop and reassess persistent/new ocular irritation, pain, chemosis, marked photophobia, keratitis or hypersensitivity. The exact product contains benzalkonium chloride 0.1 mg/ml, which may irritate the ocular surface.
  • Other antimuscarinic medicines may potentiate systemic effects. Cyclopentolate may antagonise cholinergic miotics/antiglaucoma medicines such as pilocarpine or carbachol; review the complete medication plan.
  • Separate other ophthalmic medicines by at least 5–10 minutes. Do not mix products in one preparation unless compatibility is established.
  • Avoid dropper-tip contact with the eye, lids or any surface; do not share one bottle between animals. Inspect solution clarity and bottle integrity before use.
  • Discard 28 days after first opening. Store at no more than 25°C, tightly closed in the original outer pack, protected from light and humidity.
  • Avoid during pregnancy unless the veterinarian concludes that expected benefit outweighs risk; use during lactation only after an individual benefit-risk assessment.
  • Overdose or ingestion can cause anticholinergic toxicity, including hypotension and respiratory/CNS depression. Treat as urgent exposure and contact veterinary toxicology/emergency care.
Assessment sources
  1. Cicloplegicedol exact leaflet2022
  2. Midria current register2026
  3. Midria current SPC2025
  4. Healthy Beagle cyclopentolate2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Adjunctive cycloplegia/mydriasis for ocular pain and pupillary spasm associated with corneal ulcer and/or anterior uveitis
6.4/10
Situational / acceptable
vetman assessment

Cicloplegicedol

10 mg/ml (1%), eye drops, human medicine
Assessed clinical scopeCat · Adjunctive cycloplegia/mydriasis for ocular pain and pupillary spasm associated with corneal ulcer and/or anterior uveitis · Into the eye
Care settingVeterinary ophthalmic treatment after examination, with reassessment and IOP/tear monitoring where indicated.
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-046398 · Verified on 15 Oct 2026 Off-label use

A regulator-supported but narrower feline option for ocular pain/pupillary spasm. Efficacy is plausible and labelled for the matched comparator, but elevated IOP, prolonged action and systemic absorption make patient selection and monitoring decisive.

Regulatory and scientific credibility7.5/10

The exact human product is currently authorised in Georgia and Portugal with a transparent composition/leaflet; a current Portuguese veterinary comparator matches strength and preservative, but Cicloplegicedol itself has no veterinary authorisation and clinical transfer is not product equivalence.

Clinical efficacy7.0/10

The authorised matching-strength veterinary comparator supports relief of ciliary spasm/ocular pain and prevention of posterior synechiae in corneal ulcer and/or anterior uveitis, with species pharmacodynamics; controlled diseased-eye outcome trials for the exact human product were not located.

Safety and tolerability4.5/10

Cats have reproducible IOP elevation after one drop and need baseline/ongoing IOP monitoring; systemic absorption and prolonged effects are relevant, while frequent systemic signs in a small study followed a higher two-drop-bilateral protocol rather than the usual single therapeutic drop.

Clinical practicality6.5/10

The low drop count and alternate-day maintenance are workable, but feline restraint, pre-treatment and follow-up tonometry, minimum-exposure dosing, prolonged dilation and systemic observation add meaningful clinical burden.

Full-course cost-effectiveness-

A current Georgian exact-pack price and role-specific full-course/procedure cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Human medicine. All canine/feline use of this exact Cicloplegicedol presentation is off-label; the authorised Portuguese veterinary comparator supports transfer but does not make the exact product veterinary-authorised.
  • Do not use in cats with elevated intraocular pressure. Measure IOP before use and monitor it during treatment; one-drop feline studies show a reproducible early IOP rise.
  • Use the minimum justified feline exposure. A small study using two drops 10 minutes apart in both eyes reported temporary systemic signs in 10/15 cats; do not generalise that frequency to one drop or automatically repeat bilateral dosing.
  • Stop and reassess persistent/new ocular irritation, pain, chemosis, marked photophobia, keratitis or hypersensitivity. The exact product contains benzalkonium chloride 0.1 mg/ml, which may irritate the ocular surface.
  • Other antimuscarinic medicines may potentiate systemic effects. Cyclopentolate may antagonise cholinergic miotics/antiglaucoma medicines such as pilocarpine or carbachol; review the complete medication plan.
  • Separate other ophthalmic medicines by at least 5–10 minutes. Do not mix products in one preparation unless compatibility is established.
  • Avoid dropper-tip contact with the eye, lids or any surface; do not share one bottle between animals. Inspect solution clarity and bottle integrity before use.
  • Discard 28 days after first opening. Store at no more than 25°C, tightly closed in the original outer pack, protected from light and humidity.
  • Avoid during pregnancy unless the veterinarian concludes that expected benefit outweighs risk; use during lactation only after an individual benefit-risk assessment.
  • Overdose or ingestion can cause anticholinergic toxicity, including hypotension and respiratory/CNS depression. Treat as urgent exposure and contact veterinary toxicology/emergency care.
Assessment sources
  1. Cicloplegicedol exact leaflet2022
  2. Midria current register2026
  3. Midria current SPC2025
  4. Cat cyclopentolate IOP2020
  5. Feline mydriatic IOP2006
  6. Cat systemic effects2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Diagnostic mydriasis and cycloplegia for fundus examination or refractive assessment
5.9/10
Weak evidence support
vetman assessment

Cicloplegicedol

10 mg/ml (1%), eye drops, human medicine
Assessed clinical scopeCat · Diagnostic mydriasis and cycloplegia for fundus examination or refractive assessment · Into the eye
Care settingClinic-administered ophthalmic diagnostic use with planned timing, ocular examination and species-specific post-dose observation.
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-046398 · Verified on 15 Oct 2026 Off-label use

Cyclopentolate can produce diagnostic mydriasis/cycloplegia in cats, but prolonged effects, reproducible IOP elevation and systemic signs after repeated bilateral dosing make it a weak routine default; justify exposure and monitor.

Regulatory and scientific credibility7.5/10

The exact human product is currently authorised in Georgia and Portugal with a transparent composition/leaflet; a current Portuguese veterinary comparator matches strength and preservative, but Cicloplegicedol itself has no veterinary authorisation and clinical transfer is not product equivalence.

Clinical efficacy6.5/10

One-drop and repeated-dose feline studies confirm strong, prolonged mydriasis and use for refraction, but cycloplegic adequacy is less fully quantified and duration is variable; the exact human product has no feline diagnostic trial.

Safety and tolerability4.0/10

Feline studies show IOP elevation and prolonged 24–60 hour dilation; a small two-drop-bilateral refraction study reported temporary GI/behavioural signs in 10/15 cats. That frequency cannot be assigned to one drop, but it makes automatic repeated bilateral dosing a substantial safety weakness.

Clinical practicality5.5/10

Clinic administration is simple, but tonometry, avoidance of reflex repeat bilateral dosing, prolonged 24–60 hour dilation and post-procedure observation materially reduce diagnostic practicality.

Full-course cost-effectiveness-

A current Georgian exact-pack price and role-specific full-course/procedure cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Human medicine. All canine/feline use of this exact Cicloplegicedol presentation is off-label; the authorised Portuguese veterinary comparator supports transfer but does not make the exact product veterinary-authorised.
  • Do not use in cats with elevated intraocular pressure. Measure IOP before use and monitor it during treatment; one-drop feline studies show a reproducible early IOP rise.
  • Use the minimum justified feline exposure. A small study using two drops 10 minutes apart in both eyes reported temporary systemic signs in 10/15 cats; do not generalise that frequency to one drop or automatically repeat bilateral dosing.
  • Stop and reassess persistent/new ocular irritation, pain, chemosis, marked photophobia, keratitis or hypersensitivity. The exact product contains benzalkonium chloride 0.1 mg/ml, which may irritate the ocular surface.
  • Other antimuscarinic medicines may potentiate systemic effects. Cyclopentolate may antagonise cholinergic miotics/antiglaucoma medicines such as pilocarpine or carbachol; review the complete medication plan.
  • Separate other ophthalmic medicines by at least 5–10 minutes. Do not mix products in one preparation unless compatibility is established.
  • Avoid dropper-tip contact with the eye, lids or any surface; do not share one bottle between animals. Inspect solution clarity and bottle integrity before use.
  • Discard 28 days after first opening. Store at no more than 25°C, tightly closed in the original outer pack, protected from light and humidity.
  • Avoid during pregnancy unless the veterinarian concludes that expected benefit outweighs risk; use during lactation only after an individual benefit-risk assessment.
  • Overdose or ingestion can cause anticholinergic toxicity, including hypotension and respiratory/CNS depression. Treat as urgent exposure and contact veterinary toxicology/emergency care.
Assessment sources
  1. Cicloplegicedol exact leaflet2022
  2. Midria current register2026
  3. Midria current SPC2025
  4. Cat cyclopentolate IOP2020
  5. Feline mydriatic IOP2006
  6. Cat systemic effects2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Cyclopentolate10 mg/ml
Formulation Type
Eye drops
Administration route
Into the eye
Manufacturer
Laboratório Edol · Portugal
Registration
Georgia Yes, human
In force until 01 Oct 2031
Human (Ministry of Health, RAMA)
№ რ-046398
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified All canine and feline use of this exact human product is off-label. A current Portuguese veterinary comparator has the same 10 mg/ml strength and 0.1 mg/ml benzalkonium chloride: for ocular pain/pupillary spasm associated with corneal ulcer and/or anterior uveitis, one drop in the affected eye(s) once or twice in the first 24 hours, then one drop every other day only if effect must be maintained. Do not copy the more frequent human uveitis regimen. Direct healthy-animal studies support species-specific diagnostic timing but do not establish one universal veterinary refraction protocol.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗